BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16873673)

  • 1. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
    Burmeister T; Gökbuget N; Reinhardt R; Rieder H; Hoelzer D; Schwartz S
    Blood; 2006 Nov; 108(10):3556-9. PubMed ID: 16873673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.
    Quintás-Cardama A; Tong W; Manshouri T; Vega F; Lennon PA; Cools J; Gilliland DG; Lee F; Cortes J; Kantarjian H; Garcia-Manero G
    Leukemia; 2008 Jun; 22(6):1117-24. PubMed ID: 18401417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
    Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
    Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia.
    Graux C; Cools J; Melotte C; Quentmeier H; Ferrando A; Levine R; Vermeesch JR; Stul M; Dutta B; Boeckx N; Bosly A; Heimann P; Uyttebroeck A; Mentens N; Somers R; MacLeod RA; Drexler HG; Look AT; Gilliland DG; Michaux L; Vandenberghe P; Wlodarska I; Marynen P; Hagemeijer A
    Nat Genet; 2004 Oct; 36(10):1084-9. PubMed ID: 15361874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABL1 fusions in T-cell acute lymphoblastic leukemia.
    De Keersmaecker K
    Verh K Acad Geneeskd Belg; 2008; 70(4):245-55. PubMed ID: 19166098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
    De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
    Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
    Chiaretti S; Tavolaro S; Ghia EM; Ariola C; Matteucci C; Elia L; Maggio R; Messina M; Ricciardi MR; Vitale A; Ritz J; Mecucci C; Guarini A; Foà R
    Haematologica; 2007 May; 92(5):619-26. PubMed ID: 17488685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse.
    Clarke S; O'Reilly J; Romeo G; Cooney J
    Leuk Res; 2011 Jul; 35(7):e131-3. PubMed ID: 21489623
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of a cryptic
    Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
    Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
    De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
    Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
    Hagemeijer A; Graux C
    Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
    De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
    Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion of NUP214 to ABL1 on amplified episomes in T-ALL--implications for treatment.
    Stergianou K; Fox C; Russell NH
    Leukemia; 2005 Sep; 19(9):1680-1. PubMed ID: 16015385
    [No Abstract]   [Full Text] [Related]  

  • 15. NUP214-ABL1 fusion in childhood T-ALL.
    Veltri G; Sandei M; Silvestri D; Bresolin S; Pession A; Santoro N; Ziino O; Veltroni M; Rizzari C; Biffi A; Valsecchi MG; Conter V; Buldini B; Accordi B; Serafin V
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29643. PubMed ID: 35253360
    [No Abstract]   [Full Text] [Related]  

  • 16. Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia.
    Graux C; Stevens-Kroef M; Lafage M; Dastugue N; Harrison CJ; Mugneret F; Bahloula K; Struski S; Grégoire MJ; Nadal N; Lippert E; Taviaux S; Simons A; Kuiper RP; Moorman AV; Barber K; Bosly A; Michaux L; Vandenberghe P; Lahortiga I; De Keersmaecker K; Wlodarska I; Cools J; Hagemeijer A; Poirel HA; ;
    Leukemia; 2009 Jan; 23(1):125-33. PubMed ID: 18923437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
    Barbouti A; Ahlgren T; Johansson B; Höglund M; Lassen C; Turesson I; Mitelman F; Fioretos T
    Br J Haematol; 2003 Jul; 122(1):85-93. PubMed ID: 12823349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.
    Duployez N; Grzych G; Ducourneau B; Alarcon Fuentes M; Grardel N; Boyer T; Abou Chahla W; Bruno B; Nelken B; Clappier E; Preudhomme C
    Haematologica; 2016 Apr; 101(4):e133-4. PubMed ID: 26681761
    [No Abstract]   [Full Text] [Related]  

  • 20. Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.
    Vanden Bempt M; Demeyer S; Broux M; De Bie J; Bornschein S; Mentens N; Vandepoel R; Geerdens E; Radaelli E; Bornhauser BC; Kulozik AE; Meijerink JP; Bourquin JP; de Bock CE; Cools J
    Cancer Cell; 2018 Aug; 34(2):271-285.e7. PubMed ID: 30107177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.